% | $
Quotes you view appear here for quick access.

Forest Laboratories Inc. Message Board

mirror_world_man 15 posts  |  Last Activity: Mar 25, 2015 3:39 PM Member since: Mar 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    FDA agrees on SVC primary endpoint

    by aecooter33 Mar 25, 2015 12:14 PM
    mirror_world_man mirror_world_man Mar 25, 2015 3:39 PM Flag

    One important lesson from the B-ALS is to keep energy levels up, the trial population remains well fed during the Phase 3. No empty calories...

    Sentiment: Strong Buy

  • Reply to

    The news release

    by warrenw6630 Mar 25, 2015 10:02 AM
    mirror_world_man mirror_world_man Mar 25, 2015 1:31 PM Flag

    The knee jerk is not unusual in heavily shorted BT's of which CYTK is not, so it is a bit odd. I guessed the move to PIII was giving some BB's the tizzies of an offering to pay for the trials, or some people want in at a lower price. The results look ok after only a single dose. IMHO the bottom line is that those that dumped did so on automatic pilot, or have a longer range plan. I nibbled a bit on the way down, there is no harm as far as I can see.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man Mar 21, 2015 5:22 PM Flag

    Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK, Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX. All of these carry a Zacks Rank #1 (Strong Buy). 2013 they said the same thing and CYTK popped to almost double a little later.

    Sentiment: Strong Buy

  • Reply to

    If the clsp short theory is correct,..

    by itsahorserace Jan 14, 2015 8:51 PM
    mirror_world_man mirror_world_man Jan 14, 2015 11:13 PM Flag

    purchase price is not necessarily related to price of P, but at the SP at the time of company purchase. If SP remains low, the buyout may be at a cheaper price than we immagine

  • Reply to

    latest 8k filing out

    by cln6631 Jan 9, 2015 5:49 PM
    mirror_world_man mirror_world_man Jan 10, 2015 12:09 AM Flag

    Are intangibles included in company's asset to achieve 1B for bonus purposes, or MC alone?

    Sentiment: Strong Buy

  • mirror_world_man mirror_world_man Jan 8, 2015 8:34 PM Flag

    IMHO a buyout is likely and will occur post FDA approval. SGYP has not got a marketing and sales core competency to move forward on commercialization. Likely BP suitors will look to add another drug to their current a GI agent(s) on their in-line Sales portfolio. It us fun to speculate and lots of action prior to that, I wish I waited to buy more at these prices. GLTA

    Sentiment: Strong Buy

  • mirror_world_man mirror_world_man Jan 7, 2015 4:35 PM Flag

    Seen this before, particularily in BT's. I agree with those that think it is a transfer of inexpensive ownership, with help of the lawyers and pulp media help to create FUD. Short Interest has not grown recently, suggesting perhaps they are not loading up. WRT this news, hands may be slapped, issues will be cleared, may be a medium fine or two for maybe going against ethical marketing practices. Be thankfull that all medications do not create any harm and it is not a patient or trial issue. No drugs will be pulled from the market, repeated infringments will create loftier fines in the future. So the appears of cleaner than clean will be the new norm. I just bought back in again. GLTA

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man Dec 31, 2014 10:59 PM Flag

    Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18.

    The analyst note cited four facets for its strengthened investment case:

    1) "CYTK has shown its prowess in attracting significant partnerships in the form of both Amgen and Astellas,"

    2) "each of these partners have approximately the same equity stake in CYTK as well,"

    3) "a regulatory path forward for tirasemtiv for ALS is expected in the near term and, importantly,"

    4) "the company has a strong financial footing with 2-3 years of cash on hand with the recently expanded Astellas collaboration (~$150 million pro forma cash)."

    Analyst Joseph Pantginis concluded, “While the final trial design for a pivotal study has not yet been agreed upon with the FDA and EMEA, the trial design will likely contain and adaptive design as well as important interim analyses. This should allow CYTK to "titrate" their spending on the ALS study on an "as needed basis".”

    Cytokinetics recently traded at $8.03, up 16.4 percent.

    Latest Ratings for CYTK
    Date Firm Action From To
    Nov 2014 MLV & Co. Upgrades Hold Buy
    May 2014 Leerink Swann Maintains Outperform
    Apr 2014 Piper Jaffray Downgrades Overweight Neutral

    Sentiment: Strong Buy

  • Reply to

    Absolute power corrupts absolutely.

    by itsahorserace Nov 21, 2014 3:20 PM
    mirror_world_man mirror_world_man Nov 21, 2014 5:05 PM Flag

    never underestimate the tenacity of ashorts with large positions. They will continue to cover incrementally, and slowly, using a bunch of techniques, as long as it takes, Look at ARNA as a good example, check out the short interest steadily decline while the SP remains relatively flat. Even after buy out announcements, they will continue to manipulate. Long terms hold is the play...

    Sentiment: Strong Buy

  • Regardless of the reason.

    Sentiment: Strong Buy

  • borrowing more shares to dump and bottom feeding on stops has really worked well for the shorts. lol must be some year end disparate move. Why sell at this point? Shorts cannot apply their models to any BT and expect to come out ahead all the time. Hold Strong.

    Sentiment: Strong Buy

  • Reply to


    by richinjun Nov 6, 2014 2:29 PM
    mirror_world_man mirror_world_man Nov 6, 2014 5:59 PM Flag

    based upon the financing decision to direct the proceeds to go with plecantide alone, i would guess that no development partner is in the works and SGYP will either promote it themselves with their own newly hired or contract sales force, or they will sell the molecule and receive a royalty, or go for a buy out. If anyone sees a headhunter ad for a VP of sales and reps then we know which way they will go post FDA approval. shorts will dump on any news, but are screwed.

    Sentiment: Strong Buy

  • my issue is the holders that decide to flip the 3.11 warrants and take immediate gains may help the shorts cover

    "Company may not redeem the Notes prior to the Maturity Date. Holders may surrender their Notes for conversion at any time prior to the close of business on the business day immediately preceding the Maturity Date. The initial conversion rate will be 321.5434 shares of the Company's Common Stock for each $1,000 principal amount of Notes, which represents an initial conversion price of approximately $3.11 per share. The conversion rate is subject to adjustment under certain circumstances described in the Indenture."

    Sentiment: Strong Buy

  • Reply to

    Phase 3 is likely

    by mirror_world_man Apr 29, 2014 12:40 PM
    mirror_world_man mirror_world_man Oct 20, 2014 11:09 AM Flag

    Was there any doubt, really...

  • Reply to

    Maybe another

    by wallstreetbuyer Sep 18, 2014 9:14 PM
    mirror_world_man mirror_world_man Oct 6, 2014 8:48 PM Flag

    I usually don't reply to wsb, but I had to take the bait here. The only thing I would like with another RS is the reduced OS count. Go 10:1, and watch what happens. Lol

    Sentiment: Strong Buy